Skip to main content

Protagonist Therapeutics, Inc

PTGX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001377121

In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.

13F holders, Q4 2022

Institutional positions in Protagonist Therapeutics, Inc as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
137
+5 vs. Q3 2022
Shares held
48.9M
+1.68M (+3.5%) vs. Q3 2022
Total value
$533.3M
+$135.4M (+34.0%) vs. Q3 2022
New holders
21
51 more added
Sold out
16
43 more reduced

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting PTGX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2022: 137 institutions
Q1 2021: 127 institutionsQ2 2021: 139 institutionsQ3 2021: 132 institutionsQ4 2021: 149 institutionsQ1 2022: 140 institutionsQ2 2022: 131 institutionsQ3 2022: 133 institutionsQ4 2022: 137 institutionsQ1 2023: 138 institutionsQ2 2023: 167 institutionsQ3 2023: 144 institutionsQ4 2023: 157 institutionsQ1 2024: 185 institutionsQ2 2024: 188 institutionsQ3 2024: 240 institutionsQ4 2024: 241 institutionsQ1 2025: 275 institutionsQ2 2025: 274 institutionsQ3 2025: 275 institutionsQ4 2025: 319 institutionsQ1 2026: 322 institutionsQ2 2026: 346 institutions
Value heldQ4 2022: $533.3M
Q1 2021: $1.15BQ2 2021: $2.16BQ3 2021: $820.8MQ4 2021: $1.68BQ1 2022: $1.19BQ2 2022: $422.1MQ3 2022: $398.9MQ4 2022: $533.3MQ1 2023: $1.22BQ2 2023: $1.57BQ3 2023: $945.9MQ4 2023: $1.32BQ1 2024: $1.73BQ2 2024: $2.05BQ3 2024: $2.78BQ4 2024: $2.44BQ1 2025: $3.15BQ2 2025: $3.92BQ3 2025: $4.70BQ4 2025: $6.18BQ1 2026: $8.31BQ2 2026: $9.30B
Institutions holding PTGX and their total value by quarter
QuarterHoldersValue
Q2 2026346$9.30B
Q1 2026322$8.31B
Q4 2025319$6.18B
Q3 2025275$4.70B
Q2 2025274$3.92B
Q1 2025275$3.15B
Q4 2024241$2.44B
Q3 2024240$2.78B
Q2 2024188$2.05B
Q1 2024185$1.73B
Q4 2023157$1.32B
Q3 2023144$945.9M
Q2 2023167$1.57B
Q1 2023138$1.22B
Q4 2022137$533.3M
Q3 2022133$398.9M
Q2 2022131$422.1M
Q1 2022140$1.19B
Q4 2021149$1.68B
Q3 2021132$820.8M
Q2 2021139$2.16B
Q1 2021127$1.15B

Institutions, Q4 2022

Shares, value and share of portfolio for each institution holding Protagonist Therapeutics, Inc; share changes are against Q3 2022.

Institutions holding PTGX in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Silvercrest Asset Management Group LLC240,745$2.63M0.02%−2,268−0.9%Reduced
Barclays PLC254,887$2.78M0.00%+38,893+18.0%Added
Renaissance Technologies LLC258,867$2.82M0.00%−140,900−35.2%Reduced
Jacobs Levy Equity Management, Inc284,115$3.10M0.02%+29,775+11.7%Added
Rafferty Asset Management, LLC295,348$3.22M0.03%−51,587−14.9%Reduced
JPMorgan Chase & Co303,162$3.31M0.00%+127,603+72.7%Added
Point72 Asset Management, L.P.316,500$3.45M0.01%−2,221,493−87.5%Reduced
Charles Schwab Investment Management Inc340,021$3.71M0.00%+6,378+1.9%Added
Bank of America Corp344,947$3.76M0.00%+34,898+11.3%Added
Kennedy Capital Management, Inc.350,133$3.82M0.11%+251,046+253.4%Added
Nuveen Asset Management, LLC360,714$3.94M0.00%+22,170+6.5%Added
Madison Avenue Partners, LP406,593$4.44M0.79%+406,593New
Northern Trust Corp418,607$4.57M0.00%+824+0.2%Added
Sio Capital Management, LLC434,635$4.74M2.53%+434,635New
Two Sigma Investments, LP491,965$5.37M0.02%+246,260+100.2%Added
Woodline Partners LP512,140$5.59M0.08%+512,140New
Kynam Capital Management, LP520,922$5.68M0.87%+1,710+0.3%Added
Walleye Capital LLC524,302$5.72M0.12%+421,359+409.3%Added
Two Sigma Advisers, LP603,500$6.58M0.02%+196,200+48.2%Added
Goldman Sachs Group Inc616,724$6.73M0.00%−140,355−18.5%Reduced
Adage Capital Partners GP, L.L.C.767,045$8.37M0.02%−106,000−12.1%Reduced
Deep Track Capital, LP871,493$9.51M0.41%+871,493New
Geode Capital Management, LLC879,891$9.60M0.00%+52,435+6.3%Added
Deutsche Bank AG925,662$10.1M0.01%+113,307+13.9%Added
Braidwell LP927,800$10.1M0.34%+927,800New
Dimensional Fund Advisors LP1,077,226$11.8M0.00%+256,788+31.3%Added
Millennium Management LLC1,345,389$14.7M0.02%+1,147,367+579.4%Added
Marshall Wace, LLP1,454,446$15.9M0.04%+639,720+78.5%Added
Citadel Advisors LLC2,355,314$25.7M0.03%+1,488,927+171.9%Added
Bain Capital Life Sciences Investors, LLC2,364,410$25.8M2.88%+103,838+4.6%Added
Morgan Stanley2,438,517$26.6M0.00%+210,942+9.5%Added
Johnson & Johnson2,449,183$26.7M7.77%00.0%Unchanged
Vanguard Group Inc3,097,714$33.8M0.00%+154,947+5.3%Added
RTW Investments, LP3,591,986$39.2M0.80%−584,851−14.0%Reduced
Farallon Capital Management, L.L.C.3,651,887$39.8M0.26%00.0%Unchanged
BlackRock Inc.3,652,157$39.8M0.00%+189,773+5.5%Added
State Street Corp3,792,926$41.4M0.00%−883,756−18.9%Reduced
UBS Oconnor LLC0$00.00%−232,820−100.0%Sold out
Graham Capital Management, L.P.0$00.00%−53,443−100.0%Sold out
Jump Financial, LLC0$00.00%−53,190−100.0%Sold out
Skandinaviska Enskilda Banken AB (publ)0$00.00%−48,977−100.0%Sold out
Dynamic Technology Lab Private Ltd0$00.00%−33,498−100.0%Sold out
Schonfeld Strategic Advisors LLC0$00.00%−31,814−100.0%Sold out
UBS Asset Management Americas Inc0$00.00%−27,275−100.0%Sold out
Tudor Investment Corp Et Al0$00.00%−24,332−100.0%Sold out
Trexquant Investment LP0$00.00%−22,421−100.0%Sold out
Ensign Peak Advisors, Inc0$00.00%−12,270−100.0%Sold out
Bridgefront Capital, LLC0$00.00%−12,084−100.0%Sold out
Dark Forest Capital Management LP0$00.00%−1,582−100.0%Sold out
US Bancorp0$00.00%−1,112−100.0%Sold out
Simplex Trading, LLC0$00.00%−755−100.0%Sold out
Macquarie Group Ltd0$00.00%0Sold out
TCI Wealth Advisors, Inc.0$00.00%−387−100.0%Sold out
Jefferies Group LLC––––Not filed